An Ongoing Study of Anemia Correction in Chronic Kidney Disease
- 1 March 2007
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 356 (9) , 959-961
- https://doi.org/10.1056/nejmc066568
Abstract
Evidence-based medicine assimilates available data to direct decisions regarding the care of patients. Extrapolations from epidemiologic observations and laboratory or clinical markers of disease severity have supported new treatments that were subsequently found to be without value in randomized, controlled clinical trials.1 In addition, therapies considered to be beneficial and safe owing to their effect on surrogate markers have been found to be ineffective or harmful in such trials.1,2 Even the results of randomized, controlled trials can be misleading, especially when the trials are not adequately powered.3Keywords
This publication has 6 references indexed in Scilit:
- Haemoglobin targets: we were wrong, time to move onThe Lancet, 2007
- Correction of Anemia with Epoetin Alfa in Chronic Kidney DiseaseNew England Journal of Medicine, 2006
- Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and AnemiaNew England Journal of Medicine, 2006
- Contradicted and Initially Stronger Effects in Highly Cited Clinical ResearchJAMA, 2005
- Rationale—Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney diseaseAmerican Heart Journal, 2005
- Surrogate End Points in Clinical Trials: Are We Being Misled?Annals of Internal Medicine, 1996